DDInter380 DDInter1676
A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Cimetidine {u} (Compound) treats {v} (Disease) obesity
Cimetidine {u} (Compound) binds {v} (Gene) CYP3A7-CYP3A51P
Cimetidine {u} (Compound) is included by {v} (Pharmacologic Class) Histamine H2 Receptor Antagonists
Cimetidine {u} (Compound) downregulates {v} (Gene) COTL1
Cimetidine {u} (Compound) causes {v} (Side Effect) Flatulence
Cimetidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Quinestrol
Cimetidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Indomethacin
Cimetidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Labetalol
Cimetidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Duloxetine
Cimetidine {u} may lead to a major life threatening interaction when taken with {v} Dasatinib
Cimetidine (Compound) treats obesity (Disease)
Cimetidine (Compound) binds CYP3A7-CYP3A51P (Gene)
Cimetidine (Compound) is included by Histamine H2 Receptor Antagonists (Pharmacologic Class)
Cimetidine (Compound) downregulates COTL1 (Gene)
Cimetidine (Compound) causes Flatulence (Side Effect)
Cimetidine may cause a minor interaction that can limit clinical effects when taken with Quinestrol
Cimetidine may cause a minor interaction that can limit clinical effects when taken with Indomethacin
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Labetalol
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine
Cimetidine may lead to a major life threatening interaction when taken with Dasatinib